Section of Infectious Diseases and Immunity, Imperial College London, London, United Kingdom.
Curr Opin Microbiol. 2012 Aug;15(4):434-9. doi: 10.1016/j.mib.2012.06.001. Epub 2012 Aug 10.
Invasive fungal infections have become a major cause of mortality in immunocompromised individuals. Despite the current availability of number of highly active antifungal agents, overall mortality remains around 40%. Importantly, it is clear that a failure to restore host immunity leads to worse outcomes. These observations provide clear rationale for the development of novel immunotherapies to improve outcomes in immunocompromised individuals with invasive fungal infections. In this article we summarise the key advances that have been made in the field of immunotherapy for fungal infections in recent years, with a particular focus on clinical studies of interferon-γ therapy, adoptive T cell therapy, and gene therapy for chronic granulomatous disorder. In addition a number of pre-clinical approaches are reviewed.
侵袭性真菌感染已成为免疫功能低下人群死亡的主要原因。尽管目前有许多高效抗真菌药物可用，但总体死亡率仍约为 40%。重要的是，很明显，未能恢复宿主免疫会导致更糟糕的结果。这些观察结果为开发新型免疫疗法提供了明确的依据，以改善免疫功能低下的侵袭性真菌感染患者的预后。本文总结了近年来在真菌感染免疫治疗领域取得的重要进展，特别关注干扰素-γ治疗、过继性 T 细胞治疗和慢性肉芽肿病基因治疗的临床研究。此外，还回顾了一些临床前方法。
